PriceTargets.com logo

Basilea Pharmaceutica - BPMUF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $87.00
  • Forecasted Upside: 74.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$50.00 As of 09/29/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for BPMUF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Basilea Pharmaceutica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BPMUF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BPMUF

Analyst Price Target is $87.00
▲ +74.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Basilea Pharmaceutica in the last 3 months. The average price target is $87.00, with a high forecast of $87.00 and a low forecast of $87.00. The average price target represents a 74.00% upside from the last price of $50.00.

This chart shows the closing price for BPMUF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Basilea Pharmaceutica. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/3/2022HC WainwrightBoost TargetBuy ➝ BuyCHF 84 ➝ CHF 87
9/12/2022HC WainwrightReiterated RatingBuy ➝ BuyCHF 72 ➝ CHF 84
8/18/2021Cantor FitzgeraldReiterated RatingOverweight
9/8/2020HC WainwrightReiterated RatingBuy
9/5/2019HC WainwrightReiterated RatingBuy
(Data available from 9/30/2018 forward)

News Sentiment Rating

1.08 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Basilea Pharmaceutica logo
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase ½ clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Read More

Today's Range

Now: $50.00
Low: $50.00
High: $50.00

50 Day Range

MA: $50.00
Low: $50.00
High: $50.00

52 Week Range

Now: $50.00
Low: $50.00
High: $50.00

Volume

N/A

Average Volume

N/A

Market Capitalization

$592.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Basilea Pharmaceutica?

The following Wall Street analysts have issued research reports on Basilea Pharmaceutica in the last twelve months: HC Wainwright.
View the latest analyst ratings for BPMUF.

What is the current price target for Basilea Pharmaceutica?

1 Wall Street analysts have set twelve-month price targets for Basilea Pharmaceutica in the last year. Their average twelve-month price target is $87.00, suggesting a possible upside of 74.0%. HC Wainwright has the highest price target set, predicting BPMUF will reach $87.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $87.00 for Basilea Pharmaceutica in the next year.
View the latest price targets for BPMUF.

What is the current consensus analyst rating for Basilea Pharmaceutica?

Basilea Pharmaceutica currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BPMUF will outperform the market and that investors should add to their positions of Basilea Pharmaceutica.
View the latest ratings for BPMUF.

What other companies compete with Basilea Pharmaceutica?

Other companies that are similar to Basilea Pharmaceutica include Centessa Pharmaceuticals, Enliven Therapeutics, Bicycle Therapeutics, Alpine Immune Sciences and Phathom Pharmaceuticals. Learn More about companies similar to Basilea Pharmaceutica.

How do I contact Basilea Pharmaceutica's investor relations team?

Basilea Pharmaceutica's physical mailing address is Grenzacherstrasse 487, Basel V8, 4058. The company's listed phone number is (161) 606-1111 and its investor relations email address is investor_relations@basilea.com. The official website for Basilea Pharmaceutica is www.basilea.com. Learn More about contacing Basilea Pharmaceutica investor relations.